Skip to main content
Figure 4 | BMC Pharmacology and Toxicology

Figure 4

From: Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats

Figure 4

Effects of CNX-011-67 on FFA and TG levels in male ZDF rats. CNX-011-67 reduced both serum FFA (A) and serum TG (B) in ZDF rats when compared with vehicle control rats. Data in all panels are mean ± SEM (n = 10/group). Statistical comparison between control and treatment group was conducted by unpaired Student’s t test for comparison with baseline values within groups (*p < 0.05, ** p < 0.01 and ***p < 0.001).

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us